Founded in 2019, PTM Therapeutics is a San Francisco-based, pre-clinical stage startup that strives to “develop therapeutics for the betterment of human health span and well-being.” They achieve this by harnessing antibody technology against post-translational modification (PTM) targets for gastrointestinal (GI) and oncology diseases. The company collaborates with the University of Michigan and Emory University to exclusively license these therapies to target conditions like inflammatory bowel disease (IBD). The company’s research revolves around the theory that PTMs are implicated in disease states. PTMs are chemical alterations made to proteins after they are synthesized in cells. These changes impact a protein’s structure, stability, and activity, ultimately affecting cellular processes like signaling or gene expression. PTMs are crucial for cellular functionality, allowing proteins to adopt diverse
Vaxcyte is set to raise $500 million via a stock sale to fund its work on a pneumococcal vaccine it hopes can supplant Pfizer’s Prevnar 20. The San Carlos, CA biotech plans to use the money to fund the Phase III program in older adults for VAX-24, its 24-valent pneumococcal vaccine that has each of the the 20 serotypes in Prevnar 20, plus four more. It also plans to build up its manufacturing process and capacity for an initial launch of the vaccine, according to an SEC Prospectus. Read more.
SAN DIEGO--(BUSINESS WIRE)-- Primmune Therapeutics today announced interim results from its Phase 1 study in healthy volunteers with PRTX007, a novel orally-administered, small molecule toll-like receptor 7 (TLR7) specific agonist for acute viral diseases, including SARS-CoV-2, and cancer. This double blind, placebo-controlled Phase 1 study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD), and tolerability of PRTX007 in single- and multiple-ascending dose cohorts. PRTX007 is Primmune’s lead TherAjuvant™, a reference to its combination of therapeutic and adjuvant mechanisms of action. PRTX007 is designed to provide immediate benefit to patients through controlled stimulation of the innate immune response while also potentiating long-term effective innate and adaptive immune responses. PRTX007 uniquely engages TLR7 and targeted immune cells without exacerbating inflammation, a critical feature in treating